生命科学资讯

Ice Bears swap Finstrom for blue liner Roche - Knoxville Ice Bears

Roche’s fenebrutinib shows best-in-disease potential in MS - European Pharmaceutical Review

Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena

Artificial Intelligence at Roche Diagnostics - Emerj Artificial Intelligence Research

Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed - Fierce Biotech

Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market - Yahoo Finance

Why Roche Holding Stock Popped Today - Yahoo Finance

Roche's experimental MS drug hits main goal in one of two key trials - Reuters

Roche’s MS tablet scores in late-stage studies - BioPharma Dive

Roche Rival Plunges On 'Unprecedented' Results In MS Treatment - Investor's Business Daily

Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint - Clinical Trials Arena

Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold - BioSpace

Roche's Gazyva, on an autoimmune hot streak, looks to further its new foothold in lupus with phase 3 win - Fierce Pharma

Roche signs $2B pact to pilot Manifold Bio's shuttles to the brain - Fierce Biotech

Roche taps an AI specialist to craft new brain drugs - BioPharma Dive

Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases - Business Wire

Is Roche a Hidden Gem After Its New Immunotherapy Partnerships and Share Price Dip? - Yahoo Finance

Julie Roche named 2025 Fellow of the American Physical Society - Ohio University

Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific - Fierce Biotech

Roche Earnings: We’re Slightly Lowering Our 2025 Sales Forecast but Encouraged by Diverse Pipeline - Morningstar Canada